Although administration of myeloid colony-stimulating factors (G-CSF or GM-CSF) has been routinely used to increase the rate of neutrophil recovery, evidence suggests that clinical efficacy in the transplant setting is doubtful (Table 1) . We performed two consecutive prospective randomized trials to assess the use of G-CSF (filgrastim) after autologous transplantation. The first question to be answered would be whether there is any disadvantage in delaying the administration of G-CSF. In our first trial (from May 1994 to June 1997), 80 patients randomly received G-CSF at a dose of 5 mg/kg/day from day þ 2 (36 cases) or þ 5 (44 cases) after infusion of peripheral blood stem cells (PBSC) . No differences could be observed regarding the period of aplasia (neutrophils o0.5 Â 10 9 /l), time to recover more than 20 Â 10 9 /l platelets, transfusional support, infectious complications, days with fever or days of stay. In addition, a substantial economic benefit was obtained by delaying the administration of G-CSF. Consequently, our data and those obtained by other groups 2-4 support delayed rather than early administration of G-CSF. As haematological recovery after PBSC infusion is characterized by a delay of 8-12 days -the time necessary for the differentiation of progenitor cells to mature neutrophils 5,6 -the second question to be answered is whether G-CSF should be administered in autologous PBSC transplantation. In our second trial (from July 1997 to November 1998), 62 patients randomly received G-CSF at a dose of 5 mg/kg/day from day þ 5 (30 cases) or not G-CSF (32 cases). Despite faster neutrophil engraftment in the treated group (mean of 10 vs 12 days), there were no differences between groups in the end points analysed, such as infectious complications, days with fever, transfusional support or days of stay.
7 In contrast to the report of Lee et al, 8 we demonstrated a disadvantage in the use of filgrastim on hospitalization costs. Our second conclusion, therefore, is that there is no clear beneficial impact of its administration, and is in accord with another published study. 9 We suggest that the question is not when G-CSF should be administered as suggested by Verma et al, 10 but whether myeloid growth factors need to be administered in autologous haematopoietic stem cell transplant recipients. 
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